PWZ-029: Difference between revisions
Content deleted Content added
Updating {{drugbox}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report... |
changed chembl id |
||
| Line 6: | Line 6: | ||
| image = PWZ-029_structure.png |
| image = PWZ-029_structure.png |
||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
| ChEMBL = |
| ChEMBL = 45346 |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
Revision as of 11:25, 23 January 2012
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H14ClN3O2 |
| Molar mass | 291.732 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
  (what is this?) (verify) | |
PWZ-029 is a benzodiazepine derivative drug with nootropic effects. It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.[1]
See also
References
- ^ Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Research. 2008 May 7;1208:150-9. doi:10.1016/j.brainres.2008.02.020 PMID 18394590
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |